Dueling Insider Moves: Heavy Buying Here, Big Selling ThereResideo Technologies NYSE: REZI reported first-quarter 2026 results above its outlook ranges and reaffirmed its full-year guidance, as executives cited solid execution across both its Products and Solutions and ADI Global Distribution businesses despite inflationary pressures and soft end markets.
Chief Executive Officer Jay Geldmacher said total net revenue rose 8% year over year to more than $1.9 billion. Total adjusted EBITDA was $215 million, and adjusted earnings per share were $0.65. Chief Financial Officer Mike Carlet said revenue exceeded the high end of the company’s outlook range, while adjusted EPS rose from $0.63 in the prior-year period.
Get Resideo Technologies alerts:
“Resideo’s execution continues to be steady in an uncertain global macroeconomic environment and with end markets still soft,” Geldmacher said.
Products and Solutions posts broad growth Tom Surran, president of Products and Solutions, said the segment delivered 9% year-over-year net revenue growth, including an approximately 200-basis-point favorable currency impact. The quarter also included four extra days, which added about 300 basis points to net revenue growth.
Surran said revenue grew across substantially all sales channels and product families, supported by both price and volume. In retail, growth was driven primarily by volume, with stronger demand for safety and thermostat products due to weather and regulatory changes. He said First Alert products, including the First Alert SC5 connected smoke and carbon monoxide detectors, showed increasing adoption.
The OEM channel posted its sixth consecutive quarter of year-over-year revenue growth, driven by both price and volume, while electrical distribution revenue rose on demand for BRK-branded non-connected safety products. Security channel revenue also increased, primarily from price increases on existing products.
The HVAC channel was down 1% year over year, with volume declines partially offset by higher prices tied to new products. Surran said residential HVAC conditions stabilized during the quarter, and the company saw reduced channel inventory at large HVAC distribution partners over the past three quarters.
Products and Solutions gross margin was 41.8%, up 40 basis points from a year earlier, marking the segment’s 12th consecutive quarter of year-over-year gross margin expansion. Surran said the increase was driven by factory utilization improvements, partially offset by product mix and higher fuel costs. Adjusted EBITDA rose 12% year over year.
ADI revenue rises as residential AV remains soft Rob Aarnes, president of ADI Global Distribution, said ADI net revenue increased 8% year over year. Adjusted for four extra sales days, average daily sales rose 1%. Both measures included about a 1% favorable currency impact.
Aarnes said ADI’s growth was led by security, professional audiovisual and data communications categories, partially offset by weakness in residential audiovisual tied to a soft U.S. residential market. He highlighted sequential growth in security categories, including an expected rebound in video surveillance, and stronger contributions from large accounts.
E-commerce remained a focus area for ADI, with revenue up 12% year over year and average daily sales up 5%. Exclusive brands revenue increased 7%, while generating 13% more gross margin dollars. Aarnes said ADI added approximately 60 SKUs in the quarter, including new Luma security cameras, Triad premium residential sound products and Araknis networking products.
ADI gross margin was 21.2%, down 40 basis points year over year, primarily due to higher fuel costs for freight. Operating expenses rose because of variable costs tied to the extra sales days and duplicate costs related to store and distribution center optimization. ADI income from operations was flat, while adjusted EBITDA declined by $6 million.
Inflation, pricing actions and supply chain Executives said higher freight and fuel costs affected both business segments in the first quarter. Geldmacher said Resideo has largely absorbed cost inflation in its reported results and intends to raise prices later in the second quarter to address increasing costs.
Carlet said the company expects higher fuel and freight costs during 2026 but does not anticipate material cost increases from new Section 232 tariffs or memory chips. He said pricing actions are intended to fully mitigate the increasing costs, though the timing could create a slight gross margin headwind in the second quarter.
During the question-and-answer session, Surran said Products and Solutions had worked with suppliers since last year to secure memory allocation commitments for 2026. He said only a minority of the segment’s products use memory, and those products generally use smaller-capacity memory rather than the higher-demand products used in data centers.
Separation plans advance Resideo also provided an update on its planned business separation. Geldmacher said the company achieved key milestones, including the public filing of ADI’s Form 10. He said Resideo and ADI plan to hold investor day events in New York in mid-July to introduce leadership teams and discuss each company’s strategy and value creation model.
The company expects the spin-off to be completed between the middle of the third quarter and the middle of the fourth quarter. Geldmacher said the separation is expected to create two pure-play companies with sharper strategic focus and greater financial flexibility.
Carlet said both companies are expected to focus on deleveraging, with a gross leverage target of 3 times for each business, though he said more specific details would come closer to investor day.
Outlook reaffirmed Resideo reaffirmed its full-year 2026 outlook. Carlet said the remainder of the year is now more weighted toward the second half, primarily because of a shift across fiscal quarters for ADI. The company continues to expect both business segments to deliver year-over-year revenue growth in 2026, with ADI and Products and Solutions now forecast to grow at approximately the same rate.
For the second quarter of 2026, Resideo guided for total company net revenue of $1.916 billion to $1.940 billion, adjusted EBITDA of $216 million to $230 million and fully diluted adjusted earnings per share of $0.71 to $0.75. Carlet noted the second quarter has one fewer day than the same period last year.
“Based upon what we can see today, we feel real good about how we’re thinking about the full year,” Carlet said.
About Resideo Technologies NYSE: REZIResideo Technologies, Inc, headquartered in Austin, Texas, is a global provider of home comfort, security and energy management solutions. Formed as an independent company in 2018 following its spin-off from Honeywell, Resideo leverages decades of engineering experience to deliver connected products and services to residential and light commercial customers.
The company’s core offerings include smart thermostats, security systems, video doorbells, water leak and freeze detection devices, and indoor air quality monitors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Resideo Technologies Right Now?Before you consider Resideo Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Resideo Technologies wasn't on the list.
While Resideo Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
, /PRNewswire/ -- Resideo Technologies, Inc. (NYSE: REZI), a leading global manufacturer, developer, and distributor of technology-driven sensing and controls products and solutions for residential and commercial end-markets, today announced that it is scheduled to participate at the following investor events.
JP Morgan 2026 Global Technology, Media and Communications Conference in Boston, MA on Monday, May 18, 2026. Michael Carlet, Resideo's Chief Financial Officer, will participate in a fireside chat starting at 3:30 PM ET.
Baird's 2026 Global Consumer, Technology and Services Conference in New York City on Tuesday, June 2, 2026. Michael Carlet, Resideo's Chief Financial Officer, will participate in a fireside chat starting at 12:15 PM ET.
Wells Fargo's 16th Annual Industrials & Materials Conference in Chicago, IL on Wednesday, June 10, 2026. Michael Carlet, Resideo's Chief Financial Officer, will participate in a fireside chat starting at 9:30 AM CT.
The fireside chats will be webcast live and available for replay on the Investor Relations page of the Resideo website at investor.resideo.com and archived on the Investor Relations page for a period of 30 days.
About Resideo
Resideo is a leading global manufacturer, developer, and distributor of technology-driven sensing and controls products and solutions for residential and commercial end-markets. We are a leader in the home heating, ventilation, and air conditioning controls markets, smoke and carbon monoxide detection home safety and fire suppression products markets, and security products markets. Our solutions and services can be found in over 150 million residential and commercial spaces globally, with tens of millions new devices sold annually. For more information about Resideo and our trusted, well-established brands including First Alert, Honeywell Home, BRK, Control4, and others, visit www.resideo.com.
On May 19, 2026, Resideo Technologies Inc (REZI) shares fell 5.2%, bringing the current price to $26.79. The stock has seen a significant decline, trading withi
Resideo Technologies' (REZI) transformation initiatives, Snap One integration, and product launches are expected to drive margin and EBITDA growth, especially in 2H 2026. Despite negative free cash flow and macro risks, REZI maintains robust liquidity and improved leverage, supporting resilience amid ongoing market uncertainty. With an EV/EBITDA multiple below peers and 4–6% EBITDA growth projected, REZI offers ~98% near-term upside, presenting an attractive accumulation opportunity.
Files Amended Form 10 Registration Statement Announces Scheduling Details for Resideo and ADI Investor Days Reaffirms Previously Announced Second Quarter and Full Year 2026 Outlook; Releases Segmented P&S and ADI Second Quarter 2026 Financial Outlook SCOTTSDALE, Ariz., June 4, 2026 /PRNewswire/ -- Resideo Technologies, Inc. (NYSE: REZI) ("Resideo" or the "Company"), a leading global manufacturer, developer, and distributor of technology-driven sensing and controls products and solutions for residential and commercial end-markets, today announced that in connection with the planned spin-off of its ADI Global Distribution business ("ADI") and consistent with the typical spin-off process, Resideo has filed an amended Form 10 registration statement to include the ADI financial statements for the three months ended April 4, 2026, with the U.S. Securities and Exchange Commission ("SEC"), a copy of which is available on the SEC website as well as Resideo's Investor Relations website.
What happenedAccording to an SEC filing dated April 15, 2026, QSM Asset Management Ltd established a new position in ManpowerGroup by acquiring 197,104 shares during the first quarter. The estimated transaction value, calculated using quarterly average pricing, was $5.9 million.
What else to knowThis was a new position for the fund and represented 2.9% of QSM Asset Management Ltd's 13F reportable assets under management as of March 31, 2026.Top holdings after the filing:NYSE:OXY: $14.0 million (6.9% of AUM)NYSE:PFE: $13.7 million (6.7% of AUM)NYSE:ZBH: $13.7 million (6.7% of AUM)NASDAQ:VTRS: $13.3 million (6.5% of AUM)NYSE:RIO: $12.4 million (6.1% of AUM)As of April 15, 2026, ManpowerGroup shares were trading at $30.53, down roughly 37% over the past year, underperforming the S&P 500 by about 66 percentage points.Company snapshotMetricValueMarket cap$1.4 billionRevenue (TTM)$18.0 billionNet income (TTM)($13.3 million)Dividend yield4.9%Company overviewManpowerGroup is a leading global provider of workforce solutions, serving clients through an extensive international footprint and a diversified service portfolio.
The company provides recruitment, workforce solutions, assessment, training, outsourcing, and consulting services, with revenue primarily generated from staffing and talent management offerings under the Manpower and Experis brands.It operates a global network of approximately 2,200 offices in 75 countries, earning fees from permanent, temporary, and contract placements, as well as value-added HR outsourcing and advisory solutions.Main customers include corporations and organizations seeking large-scale workforce solutions, professional resourcing, and HR process outsourcing across a range of industries and geographies.What this transaction means for investorsManpowerGroup has had a rough stretch. Shares have fallen roughly 37% over the past year -- a steep decline that reflects real headwinds in the global staffing industry. Slower hiring demand, ongoing automation anxiety, and an uncertain macroeconomic backdrop have weighed on workforce solutions companies. ManpowerGroup -- once a steady, mid-cap workhorse -- has underperformed the broader market by about 67 percentage points over the last 12 months.
Against that backdrop, QSM Asset Management's decision to open a new position here is worth a second look. This isn't a top-conviction bet -- ManpowerGroup doesn't crack the fund's top five holdings -- but the $5.9 million purchase, representing nearly 3% of QSM's total reported assets, signals that QSM sees potential value in this beaten-down name.
Staffing companies can be useful barometers for broader economic confidence: When GDP growth is strong, and job openings climb, companies often turn to staffing firms like ManpowerGroup to scale headcount quickly without the long-term commitment of full-time hires.
ManpowerGroup’s most recent earnings report offered some reasons for cautious optimism: Q4 2025 revenues came in at $4.7 billion -- up 7% year over year. Management pointed to improving stabilization in market trends and sequential progress in both revenue and profitability throughout the year. That said, the business turnaround is still -- to put it charitably -- a work in progress. Adjusted earnings per share for the full year fell 38% (in constant currency), reflecting the toll of restructuring charges and a difficult operating environment in Europe.
For long-term investors, the question is whether the stock’s current weakness reflects a temporary cyclical trough or a more structural shift in how companies source talent. QSM's move suggests at least one institutional player thinks the risk/reward is starting to look attractive at these levels -- even if it's too early to call a clear turning point for the stock.
Investors looking for broader exposure to the human capital and workforce management space might also consider ETFs like the iShares U.S. Industrials ETF (IYJ +0.85%), which includes staffing and employment services among its holdings.
Andy Gould has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Occidental Petroleum. The Motley Fool has a disclosure policy.
Launched expanded global strategic transformation program, now expected to deliver $200 million in permanent cost savings in 2028 Revenues of $4.5 billion (10% as reported, 3% constant currency) Strong demand in Asia Pacific and Latin America and in select European countries. France continued sequential improvement to achieve a flat revenue trend year over year Manpower had strong growth in the quarter. Experis impacted by soft professional demand, with stable underlying activity. Talent Solutions headwinds continue, driven by tempered permanent hiring, with rate of decline narrowing over last two quarters SG&A down year over year in constant currency reflecting strong cost management , /PRNewswire/ -- ManpowerGroup (NYSE: MAN) today reported net earnings of $0.05 per diluted share for the three months ended March 31, 2026 compared to net earnings of $0.12 per diluted share in the prior year period. Net earnings in the quarter were $2.5 million compared to net earnings of $5.6 million a year earlier. Revenues for the first quarter were $4.5 billion, a 10% increase from the prior year period.
The current year quarter included restructuring costs and strategic transformation program costs which reduced earnings per share by $0.46 in the first quarter. Excluding these charges, earnings per share was $0.51 per diluted share in the quarter representing an increase of 3% in constant currency which incorporates a higher tax rate in the first quarter of 2026.1
Financial results in the quarter were also impacted by the U.S. dollar relative to foreign currencies compared to the prior year period. On a constant currency basis, revenues increased 3% compared to the prior year period.
Jonas Prising, ManpowerGroup Chair & CEO, said, "We delivered solid performance in the quarter driven by disciplined execution and stabilization in demand trends across key markets. This marks five consecutive quarters of year over year revenue trend improvement. We grew our pipeline, saw continued momentum across the portfolio within our Manpower brand, and enhanced operating leverage through reductions in SG&A. Building on this progress and our ongoing transformational efforts, we are taking proactive steps to ensure we are positioned to succeed in any operating environment. This includes launching a strategic transformation program that is intended to not only improve our cost and margin profile, yet also enable ManpowerGroup to gain market share and deliver best-in-class client service. Further, we continue to make significant progress in advancing our AI strategy, including improving the candidate and client experience and bringing new products to market to enhance our competitive position and drive long-term value creation."
We anticipate diluted earnings per share in the second quarter will be between $0.91 and $1.01, which includes an estimated favorable currency impact of 5 cents and a 43% effective tax rate."
In conjunction with its first quarter earnings release, ManpowerGroup will broadcast its conference call live over the Internet on April 16, 2026 at 7:30 a.m. Central time (8:30 a.m. Eastern time). Prepared remarks for the conference call, webcast details, presentation and recordings are included within the Investor Relations section of manpowergroup.com.
Supplemental financial information referenced in the conference call can be found at http://investor.manpowergroup.com/.
1 The prior year period included various adjustments which reduced earnings per share by $0.32 in the first quarter which are also excluded when determining the year over year adjusted trend.
About ManpowerGroup
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently for our diversity – as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World's Most Ethical Companies for the 17th time – all confirming our position as the brand of choice for in-demand talent. For more information, visit www.manpowergroup.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended, including statements regarding trends in labor demand and the future strengthening of such demand, the Company's financial outlook, and the Company's strategic initiatives and technology investments, including our ability to increase market share and the acceleration of transformation initiatives to remove structural costs from the organization to drive efficiencies, which are subject to risks and uncertainties. The Company's actual results may differ materially from those described or contemplated in the forward-looking statements due to numerous factors. These factors include those found in the Company's reports filed with the SEC, including the information under the heading "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2025, which information is incorporated herein by reference.
We caution that any forward-looking statement reflects only our belief at the time the statement is made. The Company assumes no obligation to update or revise any forward-looking statements. We reference certain non-GAAP financial measures, which we believe provide useful information for investors. We include a reconciliation of these measures, where appropriate, to GAAP on the Investor Relations section of our website at manpowergroup.com.
ManpowerGroup
Results of Operations
(In millions, except per share data)
Three Months Ended March 31
% Variance
Amount
Constant
2026
2025
Reported
Currency
(Unaudited)
Revenues from services (a)
$
4,510.4
$
4,090.3
10.3
%
2.9
%
Cost of services
3,787.4
3,392.0
11.7
%
4.1
%
Gross profit
723.0
698.3
3.5
%
-2.8
%
Selling and administrative expenses
694.7
670.1
3.7
%
-2.2
%
Operating profit
28.3
28.2
0.5
%
-17.8
%
Interest and other expenses, net
12.9
11.5
13.3
%
Earnings before income taxes
15.4
16.7
-8.3
%
-27.5
%
Provision for income taxes
12.9
11.1
15.1
%
Net earnings
$
2.5
$
5.6
-55.4
%
-64.7
%
Net earnings per share - basic
$
0.05
$
0.12
-55.2
%
Net earnings per share - diluted
$
0.05
$
0.12
-55.2
%
-64.6
%
Weighted average shares - basic
46.7
46.8
-0.3
%
Weighted average shares - diluted
47.1
47.3
-0.4
%
(a)
Revenues from services include fees received from our franchise offices of $3.8 million for both the three months ended March 31, 2026 and 2025, respectively. These fees are primarily based on revenues generated by the franchise offices, which were $454.3 million and $418.4 million for the three months ended March 31, 2026 and 2025, respectively.
ManpowerGroup
Operating Unit Results
(In millions)
Three Months Ended March 31
% Variance
Amount
Constant
2026
2025
Reported
Currency
(Unaudited)
Revenues from Services:
Americas:
United States (a)
$
654.9
$
688.8
-4.9
%
-4.9
%
Other Americas
460.7
367.9
25.2
%
19.4
%
1,115.6
1,056.7
5.6
%
3.5
%
Southern Europe:
France
1,068.6
965.7
10.7
%
-0.3
%
Italy
474.7
397.8
19.3
%
7.5
%
Other Southern Europe
558.0
470.5
18.6
%
6.1
%
2,101.3
1,834.0
14.6
%
3.0
%
Northern Europe
790.1
730.8
8.1
%
-1.8
%
APME
510.5
476.4
7.1
%
8.1
%
4,517.5
4,097.9
Intercompany Eliminations
(7.1)
(7.6)
$
4,510.4
$
4,090.3
10.3
%
2.9
%
Operating Unit Profit (Loss):
Americas:
United States
$
2.1
$
11.3
-81.9
%
-81.9
%
Other Americas
17.0
14.2
20.9
%
14.4
%
19.1
25.5
-24.9
%
-28.5
%
Southern Europe:
France
17.1
21.0
-18.5
%
-25.1
%
Italy
28.7
24.6
16.6
%
5.5
%
Other Southern Europe
8.4
4.6
83.1
%
63.8
%
54.2
50.2
8.0
%
-2.0
%
Northern Europe
(8.2)
(18.3)
55.5
%
62.8
%
APME
21.7
20.0
7.7
%
11.4
%
86.8
77.4
Corporate expenses
(51.5)
(41.1)
Intangible asset amortization expense
(7.0)
(8.1)
Operating profit
28.3
28.2
0.5
%
-17.8
%
Interest and other expenses, net (b)
(12.9)
(11.5)
Earnings before income taxes
$
15.4
$
16.7
(a)
In the United States, revenues from services include fees received from our franchise offices of $2.4 million and $2.2 million for the three months ended March 31, 2026 and 2025, respectively. These fees are primarily based on revenues generated by the franchise offices, which were $78.4 million and $76.9 million for the three months ended March 31, 2026 and 2025, respectively.
(b)
The components of interest and other expenses, net were:
2026
2025
Interest expense
$
25.7
$
22.5
Interest income
(6.1)
(6.9)
Foreign exchange loss
0.6
0.9
Miscellaneous income, net
(7.3)
(5.0)
$
12.9
$
11.5
ManpowerGroup
Consolidated Balance Sheets
(In millions)
March 31,
December 31,
2026
2025
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
224.9
$
871.0
Accounts receivable, net
4,628.2
4,770.3
Prepaid expenses and other assets
209.7
149.1
Total current assets
5,062.8
5,790.4
Other assets:
Goodwill
1,539.4
1,544.6
Intangible assets, net
422.9
430.1
Operating lease right-of-use assets
373.9
392.7
Other assets
874.1
879.1
Total other assets
3,210.3
3,246.5
Property and equipment:
Land, buildings, leasehold improvements and equipment
523.2
526.9
Less: accumulated depreciation and amortization
405.0
403.7
Net property and equipment
118.2
123.2
Total assets
$
8,391.3
$
9,160.1
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
2,558.8
$
2,721.1
Employee compensation payable
199.4
232.3
Accrued payroll taxes and insurance
654.1
672.1
Accrued liabilities
484.9
457.6
Value added taxes payable
388.4
418.1
Short-term operating lease liability
104.6
107.4
Short-term borrowings and current maturities of long-term debt
112.4
625.0
Total current liabilities
4,502.6
5,233.6
Other liabilities:
Long-term debt
1,034.3
1,052.1
Long-term operating lease liability
287.6
304.3
Other long-term liabilities
501.3
509.8
Total other liabilities
1,823.2
1,866.2
Shareholders' equity:
ManpowerGroup shareholders' equity
Common stock
1.2
1.2
Capital in excess of par value
3,577.4
3,572.5
Retained earnings
3,734.8
3,732.3
Accumulated other comprehensive loss
(412.1)
(412.1)
Treasury stock, at cost
(4,836.3)
(4,834.3)
Total ManpowerGroup shareholders' equity
2,065.0
2,059.6
Noncontrolling interests
0.5
0.7
Total shareholders' equity
2,065.5
2,060.3
Total liabilities and shareholders' equity
$
8,391.3
$
9,160.1
ManpowerGroup
Consolidated Statements of Cash Flows
(In millions)
Three months ended
March 31,
2026
2025
(Unaudited)
Cash Flows from Operating Activities:
Net earnings
$
2.5
$
5.6
Adjustments to reconcile net earnings to net cash used in operating activities:
ManpowerGroup (MAN - Free Report) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.44 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +2.51%. A quarter ago, it was expected that this staffing company would post earnings of $0.83 per share when it actually produced earnings of $0.92, delivering a surprise of +10.84%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Manpower, which belongs to the Zacks Staffing Firms industry, posted revenues of $4.51 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.96%. This compares to year-ago revenues of $4.09 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Manpower shares have added about 3.4% since the beginning of the year versus the S&P 500's gain of 2.6%.
What's Next for Manpower?While Manpower has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Manpower was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.98 on $4.64 billion in revenues for the coming quarter and $3.77 on $18.53 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Staffing Firms is currently in the bottom 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, TrueBlue (TBI - Free Report) , has yet to report results for the quarter ended March 2026.
This blue-collar temporary staffing company is expected to post quarterly loss of $0.45 per share in its upcoming report, which represents a year-over-year change of -12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
TrueBlue's revenues are expected to be $388.7 million, up 5% from the year-ago quarter.
The headline numbers for Manpower (MAN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
I revise my rating for ManpowerGroup from "Hold" to "Buy," after analyzing its performance and prospects. The group recorded a 1Q2026 EPS beat of +4.6%, thanks to robust European growth and effective cost management. Its 2Q2026 bottom-line guidance of $0.96/share is also above the $0.93 consensus; the near-term drivers are the expansion of its AI solutions into new markets and the U.S. business's turnaround.
ManpowerGroup (NYSE:MAN) reported upbeat earnings for the first quarter on Thursday.
The company posted quarterly earnings of 51 cents per share which beat the analyst consensus estimate of 49 cents per share. The company reported quarterly sales of $4.510 billion which beat the analyst consensus estimate of $4.414 billion.
ManpowerGroup said it sees second-quarter GAAP EPS of 91 cents to $1.05, versus market estimates of 96 cents.
ManpowerGroup shares rose 1.5% to trade at $31.45 on Friday.
These analysts made changes to their price targets on ManpowerGroup following earnings announcement.
Baird analyst Mark Marcon maintained ManpowerGroup with an Outperform rating and lowered the price target from $50 to $45. Truist Securities analyst Tobey Sommer maintained the stock with a Hold and lowered the price target from $38 to $34. Considering buying MAN stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
ManpowerGroup (NYSE:MAN) reported first-quarter 2026 results that management said showed “disciplined execution and continued stabilization of revenue trends across key markets,” alongside the launch of a multi-year transformation program aimed at lowering costs and improving operating efficiency.
First-quarter results and demand trends Chairman and CEO Jonas Prising said the quarter delivered reported revenue of $4.5 billion, with organic constant-currency growth of 3%. System-wide revenue, which includes franchise operations, totaled $5.0 billion. Adjusted EBITDA margin was 1.4%, which Prising attributed to “improving demand trends as well as P&L leverage.”
Prising said the company saw strengthening conditions in manufacturing, “particularly across Europe,” and noted strong Manpower performance in key markets including France, the U.S., and Italy. He also cited “stable underlying trends” in Experis and “solid performance” in Talent Solutions, pointing to improvements in MSP and Right Management even as RPO “remains more challenged.”
On costs, Prising said the company reduced adjusted SG&A by 4% in constant currency while growing the top line, reflecting “ongoing efficiency efforts.”
Management also addressed geopolitical uncertainty. Prising said the company is “closely monitoring developments related to the conflict in the Middle East,” adding that it is “still too early to assess if there will be a broader impact.”
Transformation initiative targets $200 million of savings A central focus of the call was a newly announced global transformation program. Prising said ManpowerGroup expects the initiative to deliver $200 million in permanent cost savings in 2028. He described two main components:
A “complete redesign” of back-office operations, which he said is progressing well A front-office program that will apply best practices from the back-office work to sales, recruiting, and service delivery processes Prising said the company has made “targeted investments in automation and AI” and built a modern technology infrastructure anchored by its PowerSuite platform, with “nearly 90%” of the global business operating on the platform. He said this provides a unified technology stack and access to global data across businesses.
Prising also said the company has hired a chief enterprise transformation officer to drive execution across the enterprise. In addition, he said ManpowerGroup is reviewing its portfolio to prioritize “core, higher-return opportunities” while evaluating “opportunities to divest of non-core assets.”
On timing and geography, CFO Jack McGinnis said early savings are expected to come from the back-office work, with a majority originating in Europe where the company began its back-office transformation. For the front office, McGinnis said the company is starting in North America, with North America savings expected to begin showing in 2027 and broader “rest of the regions” savings expected in 2028.
McGinnis said the company anticipates the full $200 million to be realized in 2028 as a “run rate savings” in that year, rather than only appearing late in the year.
AI initiatives: sales, recruiting, and new client offerings President and Chief Strategy Officer Becky Frankiewicz outlined how the company is embedding AI “as a growth multiplier,” highlighting three areas: commercial scale, talent experience, and monetization through partnerships.
In France, Frankiewicz said an AI-powered sales targeting engine has generated approximately $200 million in incremental revenue by identifying high-probability opportunities and focusing sales coverage. She said the company expects to scale the tool to “roughly 50% of our markets by year-end.”
On recruiting and candidate experience, Frankiewicz said ManpowerGroup expanded PowerSuite to include a partnership with Hubert.ai for AI-powered screening and interviews. She said that in the past six months the company completed more than 25,000 AI-led interviews and reduced screening time by 67%, while achieving 87% candidate satisfaction. She added these capabilities currently support markets representing about 40% of global revenue, with plans to scale to 70% by year-end.
On monetization, Frankiewicz highlighted a partnership announced in March with SoundHound AI, which she described as focused on helping clients review and redesign workflows and accelerate adoption of AI and intelligent automation. She said the offering is part of Experis U.S.’s Accelerate AI services suite built around “humans and agents” working side by side, with plans to start in the U.S. and expand globally. Frankiewicz said it is “early days” for margin impact but said the company is encouraged by early deal economics and expects to provide updates as the offerings scale.
Frankiewicz also said “tens of thousands” of employees have completed AI fundamentals training and that over 80% of the company’s workforce is already using AI in their workflows.
Segment and brand performance, margins, and cost actions McGinnis reported adjusted EBITDA of $61 million, a 5% increase in constant currency year over year. Reported EPS was $0.05, while adjusted EPS was $0.51, slightly above the midpoint of guidance. McGinnis said restructuring and strategic transformation program costs represented $0.46 per share in the quarter.
Gross margin was 16% and came in below the low end of guidance. McGinnis attributed the shortfall to lower bench utilization in Europe and mix shifts affecting staffing margin, while permanent recruitment improved sequentially and was “as expected.” In the Q&A, he characterized the pressure as primarily mix-related, driven by stronger enterprise demand, and said pricing remained “rational.” He also said bench-related impacts were a winter phenomenon and should ease in the second quarter.
By brand, Manpower revenue grew 6% in organic constant currency, Experis declined 9%, and Talent Solutions declined 1% (an improvement versus the prior quarter). McGinnis said the Experis decline was largely driven by the timing of healthcare IT projects in the U.S.
By geography, McGinnis highlighted:
Americas: revenue of $1.1 billion, up 4% in constant currency; U.S. revenue of $655 million down 5% on a days-adjusted basis Southern Europe: revenue of $2.1 billion, up 3%; France flat in constant currency; Italy up 8% days-adjusted constant currency Northern Europe: revenue of $790 million, down 1% in organic constant currency; U.K. revenues down 2% Asia Pacific Middle East: revenue of $510 million, up 8%; Japan up 4% days-adjusted constant currency Cash flow and second-quarter guidance Free cash flow in the quarter was an outflow of $135 million, which McGinnis said was affected by payment timing in the MSP business and some working capital usage that he expects to reverse in the second quarter. The company ended the quarter with $225 million of cash and $1.1 billion of total debt, with net debt of $922 million.
For the second quarter of 2026, McGinnis guided to EPS of $0.91 to $1.10, including a favorable foreign currency impact of $0.05 per share. He forecast constant-currency revenue growth of 1% to 5% (midpoint 3%) and said EBITDA margin is projected to be up 10 basis points at the midpoint versus the prior year. He also said the company expects an effective tax rate of 43% for the second quarter and will continue to exclude restructuring and strategic transformation costs from underlying guidance.
In closing remarks, Prising said the market is stabilizing and the company is “executing with discipline,” while a dedicated group advances transformation initiatives to position ManpowerGroup for future opportunities.
About ManpowerGroup (NYSE:MAN) ManpowerGroup (NYSE: MAN) is a global leader in workforce solutions, offering a broad spectrum of staffing and talent management services. Founded in 1948 and headquartered in Milwaukee, Wisconsin, the company has grown from a temporary staffing firm to a diversified provider of workforce consultancy, recruitment, and outsourcing services. ManpowerGroup is publicly traded on the New York Stock Exchange under the ticker MAN.
The company’s service offerings are organized into four principal brands.
Further Reading Five stocks we like better than ManpowerGroup
ManpowerGroup maintains a hold rating as revenue recovery strengthens, but profitability remains under pressure, and consensus estimates appear optimistic. Q1 2026 saw credible topline improvement across France, Italy, Southern Europe, and the Manpower brand, with enterprise demand signaling early-stage recovery. Gross profit fell, gross margin missed guidance, and enterprise mix continues to weigh on margins despite cost-cutting and productivity initiatives.
State of Alaska Department of Revenue reduced its stake in ManpowerGroup Inc. (NYSE:MAN – Free Report) by 58.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,309 shares of the business services provider’s stock after selling 37,367 shares during the period. State of Alaska Department of Revenue owned approximately 0.06% of ManpowerGroup worth $781,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently modified their holdings of MAN. Quarry LP bought a new stake in shares of ManpowerGroup in the 3rd quarter valued at approximately $25,000. GAMMA Investing LLC lifted its holdings in shares of ManpowerGroup by 103.3% during the third quarter. GAMMA Investing LLC now owns 799 shares of the business services provider’s stock valued at $30,000 after acquiring an additional 406 shares during the period. True Wealth Design LLC lifted its holdings in shares of ManpowerGroup by 72.5% during the third quarter. True Wealth Design LLC now owns 802 shares of the business services provider’s stock valued at $30,000 after acquiring an additional 337 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of ManpowerGroup during the third quarter valued at $30,000. Finally, UMB Bank n.a. lifted its holdings in shares of ManpowerGroup by 122.2% during the third quarter. UMB Bank n.a. now owns 991 shares of the business services provider’s stock valued at $38,000 after acquiring an additional 545 shares during the period. 98.03% of the stock is currently owned by institutional investors.
ManpowerGroup Trading Down 1.1% Shares of MAN opened at $31.49 on Thursday. ManpowerGroup Inc. has a 52-week low of $25.15 and a 52-week high of $47.33. The stock has a fifty day moving average price of $28.37 and a two-hundred day moving average price of $30.18. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 1.12. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -85.11 and a beta of 0.84.
ManpowerGroup (NYSE:MAN – Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The business services provider reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.01. ManpowerGroup had a negative net margin of 0.09% and a positive return on equity of 7.01%. The firm had revenue of $4.51 billion for the quarter, compared to analyst estimates of $4.41 billion. During the same quarter in the prior year, the firm earned $0.44 EPS. The company’s revenue was up 10.3% on a year-over-year basis. ManpowerGroup has set its Q2 2026 guidance at 0.910-1.050 EPS. Analysts predict that ManpowerGroup Inc. will post 3.66 EPS for the current fiscal year.
Wall Street Analyst Weigh In MAN has been the subject of a number of analyst reports. Truist Financial cut their price objective on ManpowerGroup from $38.00 to $34.00 and set a “hold” rating for the company in a report on Friday, April 17th. Argus raised shares of ManpowerGroup from a “hold” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Tuesday, February 3rd. Wall Street Zen cut shares of ManpowerGroup from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. Barclays decreased their price objective on shares of ManpowerGroup from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Monday, April 13th. Finally, UBS Group upped their price objective on shares of ManpowerGroup from $29.00 to $33.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, ManpowerGroup currently has an average rating of “Hold” and a consensus target price of $37.50.
Check Out Our Latest Stock Report on ManpowerGroup
ManpowerGroup Company Profile (Free Report)
ManpowerGroup (NYSE: MAN) is a global leader in workforce solutions, offering a broad spectrum of staffing and talent management services. Founded in 1948 and headquartered in Milwaukee, Wisconsin, the company has grown from a temporary staffing firm to a diversified provider of workforce consultancy, recruitment, and outsourcing services. ManpowerGroup is publicly traded on the New York Stock Exchange under the ticker MAN.
The company’s service offerings are organized into four principal brands.
Featured Articles Five stocks we like better than ManpowerGroup
Receive News & Ratings for ManpowerGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ManpowerGroup and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEGB Group (LON:GBG) Given “Buy” Rating at Canaccord Genuity Group
NEXT HEADLINE »Royal Bank Of Canada Issues Positive Forecast for BOK Financial (NASDAQ:BOKF) Stock Price
On April 28, 2026, ManpowerGroup Inc (MAN) shares rose by 4.2%, currently trading at $31.22. The stock has experienced a 52-week range of $25.15 to $47.34, refl
, /PRNewswire/ -- ManpowerGroup (NYSE: MAN) today announced the sale of its Jefferson Wells U.S. business to Sikich for a transaction value of $100 million.
Across the U.S., Jefferson Wells delivers solutions in risk & compliance, finance & accounting, and tax – across a diverse range of industries, including to public and highly regulated companies – through project consulting, integrated resourcing and executive search. In 2025 Jefferson Wells U.S. revenues were $76 million.
"This transaction is a great outcome for our clients and shareholders as we continue to refine the portfolio to prioritize investments as part of our ongoing transformation," Jonas Prising, ManpowerGroup Chair & CEO, said. "As we move forward, we are focused on our core business—growing our Manpower, Experis, and Talent Solutions brands, while continuing to connect people to sustainable work and support clients in building the skilled workforces they need to succeed."
The transaction closed on April 30th, 2026, and will result in a gain on sale to be recognized by ManpowerGroup in the second quarter. ManpowerGroup will receive net cash proceeds at closing of approximately $88 million after working capital and other items. ManpowerGroup plans to use transaction proceeds to strengthen its balance sheet as it continues to invest for sustainable long-term growth.
Sikich is a professional services firm offering consulting, technology and compliance to the public and private sectors.
"This acquisition enhances existing capabilities across our business, including deep expertise in risk and compliance, finance and accounting, and tax, making Jefferson Wells an ideal fit as we continue to scale," said Sikich Chairman & Chief Executive Officer Christopher Geier. "Both teams share a conviction of a people first culture and the belief that clients deserve practical, actionable solutions delivered at the highest level of quality."
ABOUT MANPOWERGROUP
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently for our diversity – as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World's Most Ethical Companies for the 17th time – all confirming our position as the brand of choice for in-demand talent.
For more information, visit www.manpowergroup.com, or follow us on LinkedIn, Facebook, and Bluesky.
CHICAGO--(BUSINESS WIRE)--Sikich, a professional services company specializing in consulting, technology and compliance today announced it has acquired Milwaukee-based Jefferson Wells and their 300+ employees in the U.S. from ManpowerGroup (NYSE: MAN). Jefferson Wells delivers solutions in risk & compliance, finance & accounting, and tax – across a diverse range of industries, including to public and highly regulated companies – through project consulting, integrated resourcing and executive search.
With over 30 years of operating history in the United States, Jefferson Wells brings a well-established reputation across key sectors including financial services, technology, and energy. This acquisition complements and strengthens Sikich's existing presence in healthcare, life sciences, and manufacturing and distribution. In 2025, Jefferson Wells generated U.S. revenues of $76 million. The transaction was valued at $100 million, with net cash proceeds at closing of approximately $89 million after working capital adjustments and other items.
“This acquisition enhances existing capabilities across our business, including deep expertise in risk and compliance, finance and accounting, and tax, making Jefferson Wells an ideal fit as we continue to scale,” said Sikich Chairman & Chief Executive Officer Christopher Geier. “Both teams share a conviction of a people first culture and the belief that clients deserve practical, actionable solutions delivered at the highest level of quality.”
“We are delighted to see Jefferson Wells U.S. join Sikich, where there is strong alignment in capabilities, culture, and growth ambition”, added Ger Doyle, North America region president, ManpowerGroup. “This creates exciting opportunities for the business and its people. My sincere thanks to the teams on both sides for their hard work and professionalism in bringing this together. As we move forward, we are energized to focus on our core business and continue delivering value for our clients and candidates across North America.”
The transaction closed on April 30.
About Sikich
Sikich offers the public and private sectors a diverse platform of professional services across consulting, technology and compliance. Highly specialized and hands-on teams deliver integrated solutions rooted in deep industry experience. Our approach is strategically and thoughtfully designed to help our clients, teams and communities accelerate success.
Sikich has approximately 2,000 team members and operates across North America, EMEA and APAC.
Sikich practices in an alternative practice structure in accordance with the AICPA Professional Code of Conduct and applicable law, regulations, and professional standards. Sikich CPA LLC is a licensed CPA firm that provides audit and attest services to its clients, and Sikich LLC and its subsidiaries provide tax and business advisory services to its clients. Sikich CPA LLC has a contractual arrangement with Sikich LLC under which Sikich LLC supports Sikich CPA LLC’s performance of its professional services. Sikich LLC and its subsidiaries are not licensed CPA firms.
“Sikich” is the brand name under which Sikich CPA LLC and Sikich LLC provide professional services. The entities under the Sikich brand are independently owned and are not liable for the services provided by any other entity providing services under the Sikich brand. The use of the terms “our company”, “we” and “us” and other similar terms denote the alternative practice structure of Sikich CPA LLC and Sikich LLC.
About ManpowerGroup
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently for our diversity – as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World's Most Ethical Companies for the 17th time – all confirming our position as the brand of choice for in-demand talent. For more information, visit www.manpowergroup.com.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- The Board of Directors of ManpowerGroup (NYSE: MAN) has declared a semi-annual dividend of $0.72 per share, payable on June 15, 2026 to shareholders of record as of the close of business on June 1, 2026.
Additional financial information about ManpowerGroup, including stock history and annual shareholder reports, can be found at http://investor.manpowergroup.com.
ABOUT MANPOWERGROUP
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently for our diversity – as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World's Most Ethical Companies for the 17th time – all confirming our position as the brand of choice for in-demand talent.
As organizations struggle to turn AI investment into results, Experis advances its evolution as a global technology services leader built on the power of specialized talent and human expertise
, /PRNewswire/ -- Experis, part of the ManpowerGroup (NYSE: MAN) family of brands, today announced a global brand refresh built around a clear and differentiated market position: only Experis brings together specialized talent, technology services, and delivery expertise to help organizations turn innovation into measurable business outcomes.
New Experis logo Anchored in the idea that it takes Human Ingenuity to unlock the power of technology, the refreshed identity brings this positioning to life with a more confident, contemporary, and human-centered expression of the Experis brand. The core logo has been refined rather than reinvented, preserving brand equity while signaling a clear step forward. The evolution also reinforces Experis' new descriptor, A Global Leader in Technology Services, marking a deliberate shift from IT staffing provider to technology services leader.
The timing is deliberate. Organizations everywhere are investing heavily in AI and digital transformation, and the technology alone is not delivering the outcomes they need. What's missing is the human expertise to make it work.
"That gap is exactly where Experis lives," said Kye Mitchell, President, Experis U.S. "Every client we work with is trying to close the distance between the technology they've invested in and the outcomes they need. We close that gap, with the right talent, the right services, and the right expertise. That's 'Human Ingenuity' in practice."
"The technology market is moving faster than at any point in our history, and the organizations that win will be those that can marry technical infrastructure with human capability at a global scale," Experis Europe Brand Leader James Hallahan said. "That is exactly what Experis is built to do. This brand refresh gives us clarity, clearer language for what we do, a sharper position in a crowded market, and a brand that finally reflects the work we have been doing every day."
For clients, Human Ingenuity comes to life through Experis' enterprise AI services suite, which helps organizations move from AI experimentation to enterprise execution through specialized AI talent, governance-first delivery, and strategic technology partnerships. It is how Experis helps clients build and run AI solutions that produce real outcomes, not just pilots.
For technology professionals, Experis is introducing Say HI, the talent-facing expression of Human Ingenuity. Say HI is an invitation to bring skills, judgment, and ambition to organizations and challenges where they can make the greatest impact. It positions Experis as a career partner, not a transaction.
The refreshed brand launches globally today across Experis' digital and social channels. Rollout continues across all regional touchpoints throughout 2026.
ABOUT EXPERIS
Experis®, a global leader in technology services, provides the experience and expertise to shorten the distance between innovation and business impact in a digital world. Experis is guided by the principle that only Human Ingenuity can unlock the true potential of advanced technologies like AI. For clients, Experis offers the right mix of talent and technology to accelerate progress and deliver real-world results. For individuals, Experis has the insight, size, and scale to help tech professionals expand their skills, increase their value, and find the right opportunities. By matching talent to technology in transformative ways, Experis creates brighter futures for everyone. Experis is part of the ManpowerGroup® (NYSE: MAN) family of brands, which also includes Manpower and Talent Solutions.
For more information, visit www.experis.com, or follow us on LinkedIn.
ABOUT MANPOWERGROUP
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World's Most Ethical Companies for the 17th time; all confirming our position as the brand of choice for in-demand talent.
For more information, visit www.manpowergroup.com, or follow us on LinkedIn, Facebook, and Bluesky.
On May 28, 2026, ManpowerGroup Inc MAN shares rose 3.5% to a current price of $30.33. This uptick comes amid a 52-week range that has seen a high of $47.34 and a low of $25.15.
GF Value™ verdict: Current price is $30.33 vs GF Value™ of $67.07, indicating a 54.8% upside.GF Score™ of 66/100 suggests the stock is above average in terms of overall quality.Notable signal: No insider transactions have occurred in the last three months. Is MAN Overvalued or Undervalued? According to the GF Value™, which estimates the fair value of ManpowerGroup Inc at $67.07, the current share price of $30.33 indicates that the stock is significantly undervalued, with a margin of safety of 54.8%. This presents a potential investment opportunity for those looking at undervalued stocks. However, it is important to note that the GF Valuation label suggests it may be a "Possible Value Trap," which warns investors to approach with caution. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
The substantial difference between the market price and the GF Value™ suggests that while there is potential for growth, investors should consider the underlying financial health and other indicators before making any decisions. A deeper analysis into financial strength, profitability, and market conditions may provide further insight into the stability of this valuation.
How Does MAN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 8.2x 16.8x Currently, ManpowerGroup Inc is trading at a forward P/E of 8.2x, which is significantly below its 5-year median P/E of 16.8x. This analysis aligns with the GF Value™ verdict, further supporting the notion that the stock is undervalued relative to its historical valuation metrics.
What Does MAN's GF Score™ Tell Us? Metric Rating GF Score™ 66/100 Financial Strength 5/10 Profitability 7/10 Growth 5/10 Valuation 2/10 Momentum 4/10 The GF Score™ of 66/100 indicates that ManpowerGroup Inc is above average in terms of overall quality. The strongest aspect of the score is its profitability ranking of 7/10, suggesting that the company has maintained a reasonable level of profitability despite market challenges. However, the weakest area is the valuation rank of 2/10, indicating potential concerns about the stock's current market pricing relative to its intrinsic value.
What Are Insiders Doing with MAN Stock? There have been no insider transactions in the last three months for ManpowerGroup Inc. This lack of insider activity can suggest a neutral stance from executives, indicating they may not see an immediate need to buy or sell shares based on current market conditions or company performance.
What This Means for Investors Based on the GF Value™ analysis, ManpowerGroup Inc appears to be undervalued at its current price of $30.33 compared to the estimated fair value of $67.07. However, the potential for it to be a value trap should be carefully considered by investors.
For the complete analysis, visit the ManpowerGroup Inc MAN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MAN's GF Score™?
ManpowerGroup Inc has a GF Score™ of 66/100, indicating it is above average in terms of overall quality and potential for long-term returns.
Is MAN overvalued or undervalued?
MAN is currently undervalued based on the GF Value™ assessment, which estimates the fair value at $67.07, offering a significant upside from the current price of $30.33.
What is MAN's P/E ratio?
MAN has a forward P/E ratio of 8.2x, which is below its historical 5-year median P/E of 16.8x, further indicating it is undervalued compared to its historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
This milestone marks the 10th consecutive year of recognition on Forbes' staffing and recruiting rankings.
, /PRNewswire/ -- Manpower, a global leader in contingent staffing and part of the ManpowerGroup® (NYSE: MAN) family of brands, has been named the No. 1 Temporary Staffing Firm in the nation on Forbes' 2026 list of America's Best Temporary Staffing Firms. The independent ranking, developed in partnership with Statista, also placed Manpower among the nation's top five professional recruiting firms, marking the company's tenth consecutive year of recognition on Forbes' staffing and recruiting rankings.
Forbes Best Temporary Staffing Firms 2026 "This distinction is especially meaningful because it reflects the voices that matter most — our clients, candidates and peers," said Raj Namboothiry, Senior Vice President and Head of Manpower U.S. "Today, successful hiring requires a deep understanding of what motivates people and where they can thrive. Our teams bring that understanding to every client and candidate interaction."
Manpower's reach spans more than 70 countries, connecting hundreds of thousands of organizations with skilled talent and helping millions of people find meaningful work each year. In the U.S., the brand combines data-driven recruiting with its PowerSuite® assessment platform and MyPath® skilling program to help both employers and job seekers navigate a labor market reshaped by technology and shifting demand.
The 2026 rankings draw on feedback from approximately 13,800 recruiters, HR leaders, hiring managers and job candidates, generating more than 18,000 recommendations. Firms are ranked by the volume of recommendations received from peers, clients and candidates. Companies do not pay to participate or be selected. The full rankings are available at forbes.com.
For more information about Manpower and its staffing solutions, visit manpower.com.
ABOUT MANPOWER
Manpower® is a global leader in contingent staffing and permanent resourcing, providing companies with strategic and operational flexibility and creating talent at scale. Our talent agents and specialized recruiters leverage data-driven insights to assess, guide and place people into meaningful, sustainable employment, and our PowerSuite® tech platform enables assessment and matching to predict performance potential. Our Manpower MyPath® skilling program provides rapid skills development at scale with on-the-job training, market-based certifications, and coaching for roles in growth sectors. In this constantly shifting world, our flexible workforce solutions provide companies with the business agility needed to succeed. Manpower is part of the ManpowerGroup® (NYSE: MAN) family of brands, which also includes Experis and Talent Solutions.
For more information about Manpower, visit www.manpower.com or follow us on LinkedIn.
ABOUT MANPOWERGROUP
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World's Most Ethical Companies for the 17th time; all confirming our position as the brand of choice for in-demand talent.
For more information, visit www.manpowergroup.com, or follow us on LinkedIn, Facebook, and Bluesky.
Employers cite economic uncertainty, above AI, as the key driver of hiring caution, while many continue to hire selectively for growth
, /PRNewswire/ -- Global hiring momentum remains steady year-over-year yet shows caution quarter-over-quarter, according to ManpowerGroup's latest Employment Outlook Survey of more than 40,500 employers across 42 countries. The global Net Employment Outlook (NEO) for Q3 2026 stands at 26%, down five points from the previous quarter, though up two points from the same period last year. Outlooks weakened in 33 of 42 countries compared to last quarter.
ManpowerGroup’s Employment Outlook Survey reveals employer hiring expectations for Q3 2026.
The most in-demand technical skills according to the Q3 2026 ManpowerGroup Employment Outlook Survey.
The most valuable soft skills according to the Q3 2026 ManpowerGroup Employment Outlook Survey.
Yet beneath the headline number, a more complex picture is emerging. Mid-size organizations (250–999 employees) report the strongest hiring intentions globally at 32%, alongside the largest year-over-year gains (+6 points), outpacing both small businesses and large enterprises.
"What the data this quarter reveals is a labor market navigating uncertainty while pursuing selective opportunity," said Jonas Prising, ManpowerGroup Chair & CEO. "Economic uncertainty, more than AI itself, is emerging as the primary driver of caution, particularly across Europe, Asia, and large enterprises. At the same time, many employers are continuing to hire selectively for the skills that will help them transform their businesses, accelerate productivity, and prepare for long-term growth. The organizations moving forward most confidently are those aligning their people strategy with their technology strategy."
While 42% of organizations plan to increase staff in Q3, down from 45% last quarter, 40% plan to maintain current headcount and 16% anticipate reductions. Anticipated hiring increases are driven primarily by company expansion; expected decreases are fueled by economic challenges.
AI Drives Productivity Gains, But Human Judgment Remains the Most Valued Hiring Tool
AI continues to reshape how organizations think about productivity and the workforce, and the Q3 data shows employers aren't ready to hand over the keys to AI entirely.
Despite growing AI adoption, a person reviewing resumes (57%) remains the most valued hiring resource, ranked above all AI and automated tools:
Automated status update and communication tools: 48% AI-assisted job description writing: 46% AI-driven resume screening, parsing, and sourcing: 44% AI-enhanced tools helping workers understand their skills, career paths, and opportunities: 43% Always-on AI solutions matching people and roles, with final human oversight: 41% At the same time, as employers navigate AI integration, the people skills commanding the highest premiums reveal where human value is concentrating:
Communication, collaboration, and teamwork: 72% Critical thinking and problem-solving: 68% Professionalism and work ethic: 68% Adaptability and willingness to learn: 68% Time management and prioritization: 64% Sector and Regional Highlights
Sector Insights
Even traditionally resilient sectors are feeling the pull of a more cautious environment, though some are holding their ground more than others. Information (32%) and Construction & Real Estate (31%) report the strongest hiring plans for Q3 2026, followed by Finance & Insurance (29%). Utilities & Natural Resources posted the strongest year-over-year improvement, up eight points, signaling selective areas of renewed demand. Hospitality (14%) reports the most cautious hiring plans this quarter, the sector's lowest reading since Q3 2021. Regional Hiring Plans
Year-over-year trends reveal a widening geographic divide. The Americas is the only region to strengthen compared to the same period last year, while Europe and Asia Pacific, regions with greater exposure to energy cost pressures linked to ongoing geopolitical instability, are seeing the steepest declines in employer confidence, both quarter-over-quarter and year-over-year. The Americas posted the most resilient regional outlook this quarter, declining just three points quarter-over-quarter while improving seven points year-over-year; the only region to strengthen on an annual basis. Puerto Rico (48%) and the United States (45%) are among the global leaders in hiring confidence. Brazil (37%) also posts a strong result. Asia Pacific posts a 28% NEO, down 11 points quarter-over-quarter and one point year-over-year. India (48%) leads global hiring confidence, while China (33%) and Vietnam (28%) remain positive. Europe and the Middle East reports the weakest regional outlook at 16%, down seven points quarter-over-quarter and three points year-over-year. The United Kingdom (37%) is a regional standout, while Slovakia (-6%) and Romania (-12%) post the weakest results globally. To explore global hiring trends in detail, explore the complete Q3 2026 ManpowerGroup Employment Outlook Survey.
The next survey will be released in September 2026, reporting hiring expectations for Q4 2026.
ABOUT THE SURVEY
The ManpowerGroup Employment Outlook Survey, now in its 64th year, is the most comprehensive, forward-looking employment survey of its kind, used globally as a key labor market indicator. The Net Employment Outlook (NEO) is derived by taking the percentage of employers anticipating an increase in hiring activity and subtracting from this the percentage of employers expecting a decrease in hiring activity.
SURVEY METHODOLOGY
The data for the third quarter was collected between April 1–30, 2026. The findings are based on interviews with 40,592 public and private employers across 42 countries to measure anticipated employment changes and trends. The results reflect employer sentiment at the time of data collection and may not capture the potential impact of subsequent events. Size of organization and sector are standardized across all countries and territories to allow international comparisons.
ABOUT MANPOWERGROUP
ManpowerGroup® (NYSE: MAN), the leading global workforce solutions company, helps organizations transform in a fast-changing world of work by sourcing, assessing, developing, and managing the talent that enables them to win. We develop innovative solutions for hundreds of thousands of organizations every year, providing them with skilled talent while finding meaningful, sustainable employment for millions of people across a wide range of industries and skills. Our expert family of brands – Manpower, Experis, and Talent Solutions – creates substantially more value for candidates and clients across more than 70 countries and territories and has done so for more than 75 years. We are recognized consistently as a best place to work for Women, Inclusion, Equality, and Disability, and in 2026 ManpowerGroup was named one of the World's Most Ethical Companies for the 17th time; all confirming our position as the brand of choice for in-demand talent.
For more information, visit www.manpowergroup.com, or follow us on LinkedIn, Facebook, and Bluesky.
FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements, including statements regarding labor demand in certain regions, countries and industries, and economic uncertainty. Actual events or results may differ materially from those contained in the forward-looking statements, due to risks, uncertainties and assumptions. These factors include those found in the Company's reports filed with the U.S. Securities and Exchange Commission (SEC), including the information under the heading "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2025, whose information is incorporated herein by reference. ManpowerGroup disclaims any obligation to update any forward-looking or other statements in this release, except as required by law.
New Experis research reveals CIOs' top priorities have shifted dramatically in just one year, as AI transforms what leadership requires.
, /PRNewswire/ -- One year ago, cybersecurity kept CIOs up at night. Today, business-IT alignment has overtaken cybersecurity as the top CIO priority for the first time, as technology leaders face rising pressure to prove the business value of AI investments. According to the CIO 2026 Outlook report released today by Experis, a global leader in technology services and part of the ManpowerGroup® (NYSE: MAN) family of brands, CIOs are under greater pressure than ever to translate technology potential into measurable business results, even as their peers struggle to grasp what that requires.
CIOs share the tech skills that matter most The report draws on responses from 1,930 technology leaders across 12 countries, expanding significantly from the 1,400 respondents across nine countries surveyed in 2025. The broader sample reflects growing global urgency around the CIO function as AI moves from proof of concept to proof of value.
"CIOs are being asked to lead AI transformation, drive growth, improve productivity, and manage risk all while facing significant talent shortages," said Kye Mitchell, President of Experis U.S. "When 61% of technology leaders say their C-suite peers don't fully understand the CIO role, it creates a barrier to execution. The organizations that will win with AI are the ones that treat technology leadership as a business leadership function and invest accordingly."
Key Findings:
Business-IT alignment surges to the top CIO priority: Nearly half (48%) of IT leaders say aligning IT strategy with business objectives is the most important thing a CIO can do, up sharply from 34% in 2025 — overtaking cybersecurity for the first time. Keeping pace with change is now the #1 business barrier: 44% of tech leaders cite the pace of technological innovation as their top challenge, up from 34% in 2025. The pressure is most acute in Israel (63%), Sweden (57%), and Switzerland (56%). AI is generating returns, but scrutiny is rising: 54% of tech leaders say AI investments are already producing positive ROI. Still, 31% believe their organizations are overinvesting in AI, and just 17% classify delivering AI solutions as a top CIO responsibility. CIOs remain misunderstood: 61% of tech leaders say their senior leader peers do not fully understand the CIO role and its responsibilities, up from 49% in 2025. Training and risk strategies are slipping: Just 72% of IT leaders say their risk strategy aligns with their cybersecurity readiness, down from 77% in 2025. Only 72% conduct regular cybersecurity training, a slight decline from 74% last year. Digital sovereignty concerns grow despite offshore expansion: 81% of IT leaders name digital sovereignty a high priority, yet 67% plan to increase their dependence on offshore or nearshore IT delivery in 2026. Cybersecurity skills remain most in demand: 46% of tech leaders identify cybersecurity as the most important skill their IT teams need, followed by AI and machine learning (37%) and cloud computing (31%). Talent acquisition and retention persist as a top challenge: CIOs continue to struggle to find workers with rapidly evolving tech skills, with traditional hiring approaches falling short of the pace of change. "One of the most striking findings in this year's data is the gap between stated priorities and actual behavior on sovereignty," James Hallahan, Experis Europe Brand Leader, said. "Eighty-one percent of tech leaders say digital sovereignty is a high priority, yet two-thirds are planning to increase their dependence on offshore delivery. In Europe, where regulatory exposure and geopolitical risk make data residency a board-level conversation, that disconnect has real stakes. Organizations need to decide what sovereignty actually means to them operationally, not just rhetorically, before the gap between their stated priorities and their actual investments becomes a liability."
Six in ten tech leaders are actively implementing AI-based technologies into current systems. One-third (34%) report that automation and AI-powered solutions are delivering the best ROI in production, while 41% still see cloud computing and scalable digital infrastructure as the top ROI drivers. Cybersecurity and digital sovereignty top the list of priorities earmarked for budget increases in 2026 even as the share of IT leaders whose risk strategy aligns with their cybersecurity readiness has declined, from 77% in 2025 to 72% today.
For the full report and insights, visit www.experis.com/cio-outlook.
ABOUT EXPERIS
Experis®, a global leader in technology services, provides the experience and expertise to shorten the distance between innovation and business impact in a digital world. Experis is guided by the principle that only human ingenuity can unlock the true potential of advanced technologies like AI. For clients, Experis offers the right mix of talent and technology to accelerate progress and deliver real-world results. For individuals, Experis has the insight, size, and scale to help tech professionals expand their skills, increase their value, and find the right opportunities. By matching talent to technology in transformative ways, Experis creates brighter futures for everyone. Experis is part of the ManpowerGroup® (NYSE: MAN) family of brands, which also includes Manpower and Talent Solutions.
For more information, visit www.experis.com, or follow us on LinkedIn.
Wall Street expects a year-over-year increase in earnings on higher revenues when Ultragenyx (RARE - Free Report) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis biotechnology company is expected to post quarterly loss of $1.55 per share in its upcoming report, which represents a year-over-year change of +1.3%.
Revenues are expected to be $161.26 million, up 15.8% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 5.07% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Ultragenyx?For Ultragenyx, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.05%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Ultragenyx will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Ultragenyx would post a loss of$1.2 per share when it actually produced a loss of -$1.29, delivering a surprise of -7.50%.
Over the last four quarters, the company has beaten consensus EPS estimates just once.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Ultragenyx doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAmong the stocks in the Zacks Medical - Biomedical and Genetics industry, Grail (GRAL - Free Report) , is soon expected to post loss of $3 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +3.2%. This quarter's revenue is expected to be $40.47 million, up 27.1% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Grail has remained unchanged. Nevertheless, the company now has an Earnings ESP of -2.67%, reflecting a lower Most Accurate Estimate.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Grail will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m.
Arcutis Biotherapeutics, Inc. (ARQT - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report, which is expected to be released on May 6, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of +90%.
Revenues are expected to be $99.15 million, up 50.6% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 40% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Arcutis Biotherapeutics?For Arcutis Biotherapeutics, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -20.00%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Arcutis Biotherapeutics will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Arcutis Biotherapeutics would post earnings of $0.03 per share when it actually produced earnings of $0.13, delivering a surprise of +333.33%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Arcutis Biotherapeutics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAmong the stocks in the Zacks Medical - Biomedical and Genetics industry, Ultragenyx (RARE - Free Report) , is soon expected to post loss of $1.55 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +1.3%. This quarter's revenue is expected to be $161.26 million, up 15.8% from the year-ago quarter.
The consensus EPS estimate for Ultragenyx has been revised 5.1% higher over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -0.05%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Ultragenyx will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Ultragenyx (RARE - Free Report) came out with a quarterly loss of $1.84 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $1.57 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -18.96%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.2 per share when it actually produced a loss of $1.29, delivering a surprise of -7.5%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Ultragenyx, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $136 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 15.66%. This compares to year-ago revenues of $139.29 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ultragenyx shares have added about 7.9% since the beginning of the year versus the S&P 500's gain of 5.2%.
What's Next for Ultragenyx?While Ultragenyx has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ultragenyx was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.25 on $184.41 million in revenues for the coming quarter and -$4.49 on $750.36 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Iovance Biotherapeutics (IOVA - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.
This biotechnology company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +47.2%. The consensus EPS estimate for the quarter has been revised 18.2% lower over the last 30 days to the current level.
Iovance Biotherapeutics' revenues are expected to be $77.11 million, up 56.3% from the year-ago quarter.
For the quarter ended March 2026, Ultragenyx (RARE - Free Report) reported revenue of $136 million, down 2.4% over the same period last year. EPS came in at -$1.84, compared to -$1.57 in the year-ago quarter.
The reported revenue represents a surprise of -15.66% over the Zacks Consensus Estimate of $161.26 million. With the consensus EPS estimate being -$1.55, the EPS surprise was -18.96%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ultragenyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Dojolvi: $18 million compared to the $20.67 million average estimate based on six analysts. The reported number represents a change of +5.8% year over year.Revenues- Evkeeza: $18 million versus $16.22 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +63.2% change.Revenues- Mepsevii: $7 million versus the six-analyst average estimate of $9.37 million. The reported number represents a year-over-year change of -16.5%.Revenues- Total Crysvita Revenue: $93 million compared to the $114.17 million average estimate based on five analysts.Revenues- Product sales: $89 million versus $94.98 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.7% change.Revenues- Royalty revenue: $47 million versus the four-analyst average estimate of $62.78 million.View all Key Company Metrics for Ultragenyx here>>>
Shares of Ultragenyx have returned +8.5% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Key Takeaways Ultragenyx Q1 revenues fell 2% as Crysvita sales declined due to seasonal and ordering effects.RARE saw Evkeeza sales jump 64% on new country launches and early access demand.Ultragenyx expects FDA decisions on UX111 and DTX401 later in 2026 amid other pipeline progress. Ultragenyx Pharmaceutical (RARE - Free Report) reported first-quarter 2026 loss of $1.84 per share, wider than the Zacks Consensus Estimate of a loss of $1.55. The company had incurred a loss of $1.57 per share in the year-ago quarter.
Ultragenyx’s total revenues amounted to $136 million in the reported quarter, which declined 2% year over year due to lower product sales. The top line missed the Zacks Consensus Estimate of $161 million.
The company markets four drugs, namely Crysvita, Mepsevii, Dojolvi and Evkeeza. Crysvita is approved for treating X-linked hypophosphatemia, an inherited disorder and tumor-induced osteomalacia, an ultra-rare disease. Mepsevii is approved to treat Mucopolysaccharidosis VII, also known as Sly syndrome. Dojolvi is approved for treating all forms of long-chain fatty acid oxidation disorders. Evkeeza is indicated for homozygous familial hypercholesterolemia (HoFH).
In 2022, Ultragenyx announced a license and collaboration agreement with Regeneron Pharmaceuticals (REGN - Free Report) for Evkeeza, which is approved in multiple geographies as a first-in-class therapy for use together with diet and other low-density lipoprotein-cholesterol-lowering therapies to treat adults and adolescents aged 12 years and older with HoFH. Per the deal, RARE has obtained the rights to develop, commercialize and distribute Evkeeza outside the United States. The regions include the European Economic Area. The collaboration with Regeneron for Evkeeza gives Ultragenyx a fourth approved product that adds to the top line. However, REGN solely commercializes Evkeeza in the United States.
RARE’s Q1 Results in DetailCrysvita’s total revenues were $93 million, down 10% year over year, due to expected seasonality in the U.S. and Canada and ordering patterns in Brazil. Crysvita’s net product revenues in the first quarter of 2026 included $39 million from North America, $46 million from Latin America and Turkey, and $8 million from Europe.
Mepsevii product revenues decreased 13% year over year to $7 million in the reported quarter. Dojolvi product revenues were $18 million, up 6%, driven by new patient demand. Evkeeza recorded sales of $18 million in the first quarter, up 64%, driven by increased demand from new country launches and early access.
Year to date, shares of Ultragenyx have gained 8.7% against the industry’s 2.4% decline.
Image Source: Zacks Investment Research
Operating expenses of $305 million in the quarter rose 8% year over year due to increased investments in multiple late-stage pipeline programs and marketing costs for approved drugs. Operating expenses included research and development (R&D) expenses of $187 million (up 13%), selling, general and administrative (SG&A) expenses of $88 million (up 1%) and cost of sales of $30 million (up 3%).
Cash, cash equivalents and marketable securities amounted to $534 million as of March 31, 2026, compared with $737 million as of Dec. 31, 2025.
RARE Reiterates 2026 Financial GuidanceUltragenyx continues to expect total revenues in 2026, excluding potential revenues from new product launches, between $730 million and $760 million, which suggests growth of approximately 8-13% compared to 2025.
Crysvita revenues in 2026 are expected to be in the range of $500-$520 million, indicating growing underlying global demand partially offset by the expected timing of ordering patterns in Brazil. On the other hand, Dojolvi revenues are expected to be between $100 million and $110 million in 2026.
RARE’s Key Pipeline UpdatesIn April 2026, the FDA accepted the resubmitted biologics license application (BLA) seeking accelerated approval of UX111 for the treatment of MPS IIIA. The application included extensive long-term data with follow-up of up to eight years. The data showed sustained clinical benefits compared with the decline seen in natural history studies, along with durable treatment effects across multiple clinical measures and biomarkers, while maintaining an acceptable safety profile. A final decision from the regulatory body is expected on Sept. 19, 2026.
Ultragenyx’s GTX-102, an investigational antisense oligonucleotide, is being developed in the pivotal phase III Aspire study for treating Angelman syndrome (AS) patients with a genetically confirmed diagnosis of UBE3A deletion. Top-line data is expected in the second half of 2026. Enrollment in the phase II/III Aurora study is currently ongoing to evaluate the safety and efficacy of GTX-102 for treating other AS genotypes in other patient age groups, with the first patient dosed in October 2025. This additional study aims to enable treatment for a broader range of AS patients.
The FDA has also accepted for review Ultragenyx’s BLA for its investigational AAV8 gene therapy, DTX401, to treat glycogen storage disease type Ia. A final decision from the FDA is expected on Aug. 23, 2026. The regulatory body also recently informed RARE that an Advisory Committee meeting is not anticipated at this time. Ultragenyx is also evaluating UX701, an investigational AAV9 gene therapy, in a phase I/II/III Cyprus2+ study to treat Wilson disease and expects to share top-line data later in 2026.
RARE’s Zacks Rank & Stocks to ConsiderUltragenyx currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Inovio Pharmaceuticals (INO - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have declined from $2.82 to $2.79. CPRX shares have gained 32.3% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Inovio Pharmaceuticals’ 2026 loss per share have narrowed from $1.26 to $1.06. INO shares have plunged 34.5% year to date.
Inovio Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 57.94%.
May 06, 2026 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's Chief Financial Officer and Executive Vice President and Joshua Higa, Chief of Staff and Vice President of investor relations, will participate in a fireside at Bank of America’s 2026 Healthcare Conference on Tuesday, May 12, 2026, at 2:20 PM PT.
The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa [email protected]
Developing a new drug can cost a billion dollars and take more than a decade. That makes investing in new treatments in the rare disease space — where patient populations are small, and the chance of earning a return on that investment even smaller — a risky bet for big pharmaceutical companies.
That's a big reason why 95% of the more than 10,000 rare diseases that exist do not have an FDA-approved treatment.
But for parents of children diagnosed with those diseases, doing nothing is not an option. And that's fueling a major trend in the rare disease community: medical innovation and breakthroughs that are being driven by the patient groups themselves.
Last October, Rare As One — a project funded by the Chan Zuckerberg Biohub that supports patient-led research in the rare disease space — released a report that showed of the 20 organizations it funded when the program launched in 2019, half of them were involved in clinical trials within five years.
That's remarkable progress from advocacy groups that are mostly led by the communities they represent – regular parents from varied backgrounds, partnering with researchers and clinicians to develop life saving treatments for their loved ones. But for many of these families, figuring out where to start that process can be incredibly complicated.
Ultragenyx, an established player in rare and ultra-rare drug development, is looking to fill that gap and provide families and patient advocates the tools and resources for discovering a treatment.
Twice a year the company hosts Rare Bootcamp, a multi-day forum that helps families learn about conducting rare disease research and the important steps that go into developing a new drug. It also lets them connect with others going through a similar experience.
The event is free for attendees, and is sponsored by other biotech firms, such as Alexion, BioMarin, GeneDx and BridgeBio, that also send experts to participate in panels.
During its most recent bootcamp in Boston last month, the company held more than 20 sessions covering the full spectrum of drug development, from early science to regulatory approval.
Ultragenyx founder and CEO Emil Kakkis launched the bootcamps nine years ago, inspired by his own difficulties researching new treatments during his early days in the industry.
"There's no book, there's no 'CliffsNotes' on how to develop a drug," Kakkis said.
"I struggled and struggled, and I promised myself at that time that if I ever became in the position that I knew how to do it, I was just going to tell everyone else that needed it," Kakkis said.
Mike and Evelyn Ribadeneyra attended the most recent bootcamp. They are trying to find a treatment for their daughter Abbie, who suffers from hereditary spastic paraplegia type 26, a progressive neurodegenerative disorder that took two decades to diagnose.
While they said they did not initially start their journey expecting to find a cure for their daughter's condition, in the past year they discovered that a gene therapy existed for a similar disorder called SPG 50.
"We've been on a long journey, but our new journey begins at rare disease boot camp," Mike Ribadeneyra said.
The Ribadeneyras came to Boston to receive a roadmap for how to convince others to conduct research on behalf of their child, and to develop a proof of concept for the drug.
"I didn't know what to expect, but it has been overwhelming. The access that we've been given to the researchers, specialists, and doctors … I feel like they're really in our community now," Evelyn said.
The event also serves as a gathering place for families and advocates navigating similar circumstances. Through networking sessions at the conference and dinners at the end of the day, attendees share tips and compare notes on their rare disease journeys.
"We felt so alone for so many years, and my daughter feels so alone … and to know that there are other people going through the exact same process is really encouraging," Mike said.
Laura Wilson attended the event to help her daughter Ellia, who was diagnosed with a rare neurodevelopmental disorder called ReNU2.
Wilson spent about nine years without a formal diagnosis for Ellia, as the gene was only identified in April 2025. She recently founded an organization called ReNU2 United to help families affected by the disease. So far, about 60 families in 17 countries have identified that their child has the disorder.
Wilson attended Ultragenyx's bootcamp to hear from experts in the room about developing treatments, and to learn best practices from other families that have used their organizations to support research.
"No one in this room has a child with the same disorder that my child has, but we share so much in common," Wilson said in an interview.
"That experience of being a parent to a child with a rare disorder is so unifying that, you know, you sort of get it right away," Wilson said.
The bootcamp, which is co-hosted by the EveryLife Foundation — an advocacy group founded by Kakkis in 2009 — has grown through word of mouth. Roughly two dozen attendees attended last month's event, and since it launched about 235 people from 142 organizations have completed the program.
It's also inspired other similar events, like the RARE Advocate Development Brain Workshop. That workshop focuses on rare diseases that attack the central nervous system, and is hosted by the Rare Epilepsy Network, Mahzi Therapeutics and the advocacy group Global Genes.
Ultimately though, Kakkis says he's looking forward to the day that these types of events will no longer be needed.
"My hope some day is that we'll fix this problem," Kakkis said. "And we'll know that it's fixed, because we won't see any more parents having to develop their own drugs. They'll all be done. That's what I'm hoping for."
For more stories like this, sign up for the CNBC Cures Newsletter.
May 22, 2026 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company’s common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab's potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.
If you currently own RARE and purchased prior to August 03, 2023 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab’s potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.
If you currently own RARE and purchased prior to August 03, 2023 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA® in IgG4-RD
Real-World Evidence Supports TAVNEOS® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated Vasculitis
, /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.
New data from the Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) provide insights into the biology of immunoglobulin G4-related disease (IgG4-RD),1 while additional analyses support its long-term safety profile and sustained results in IgG4-RD.2 Additionally, new real-world evidence on TAVNEOS® (avacopan) further support its established efficacy and safety profile with reduced steroid use in people living with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis.3
"Patients living with rare autoimmune diseases still face significant unmet medical needs despite advances in treatment, with conditions often being difficult to diagnose and challenging to manage," said Paul Burton, M.D., Ph.D., chief medical officer at Amgen. "The data we're presenting at EULAR deepen our understanding of disease biology and demonstrate the strength of our portfolio of options for patients with these conditions, reflecting our commitment to advancing the science and delivering meaningful progress for patients."
Key presentations include:
Long-term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from Year 1 of the Open-Label Period (OLP) of the Phase 3 MITIGATE Trial
Abstract #POS0440, Poster View 1 (Poster View Presentation), Wednesday, June 3 from 3:30–4:30 p.m. BST
IgG4-RD is a chronic and debilitating condition, marked by recurrent, unpredictable flares that can potentially impact multiple organs.4,5 New Phase 3 MITIGATE data further support the longer-term clinical profile of UPLIZNA.
Key findings include:
In the first year of the OLP, these data demonstrated sustained results and disease control with continued UPLIZNA treatment in patients with IgG4-RD. No patients (0%) who received UPLIZNA in the randomized controlled period (RCP) and continued with UPLIZNA in the OLP (N=56) experienced a flare, and 71.4% achieved flare-free, glucocorticoid-free complete remission at year 1 of the OLP.2 5.9% of patients who received placebo in the RCP and transitioned to UPLIZNA in the OLP (N=51) experienced a flare, and 41.2% achieved flare-free, glucocorticoid-free complete remission at year 1 of the OLP.2 Safety results were consistent with the established safety profile of UPLIZNA. The most common adverse events in the OLP were COVID-19, upper respiratory tract infection, cough and influenza.2 Across the combined RCP and OLP period, median total UPLIZNA treatment exposure was 2.2 years among participants who received ≥1 dose of inebilizumab.2 "For clinicians, a sustained reduction in flares and timely intervention are central to improving long-term outcomes," said John Stone, M.D., M.P.H., principal investigator and a professor of medicine at Harvard Medical School and the Edward A. Fox Chair in Medicine at the Massachusetts General Hospital. "The new MITIGATE data reinforce the long-term safety and efficacy profile of UPLIZNA while advancing our understanding of how IgG4-RD progresses over time. These findings may help clinicians identify opportunities for earlier intervention and reduce avoidable flares."
Natural History of IgG4-RD: Patterns of Organ Involvement and Flare-associated Biomarker Changes in the Phase 3 MITIGATE Trial
Abstract #OP052, Basic and Clinical Abstract Sessions: Insights in Other Diseases (Oral Abstract Presentation), Wednesday, June 3 from 4:30–4:40 p.m. BST
The first-of-its-kind natural history analysis reinforced the chronic and unpredictable nature of IgG4-RD, underscoring widespread and diverse multi-organ involvement and the need for earlier intervention and more comprehensive monitoring and risk stratification.
Key findings include:
Dynamic patterns of organ involvement over time, including the emergence of new organ manifestations and biological signals that may precede disease flares.1 CD19+ B cells were the first biomarker to rise ahead of a flare, followed by increases in total IgG and IgG subsets within the 30-day window preceding a flare.1 An additional exploratory combined analysis (Abstract #POS0089) of clinical trial RCP and OLP data in MITIGATE (N=119) showed how long-term use of UPLIZNA resulted in mostly mild immunoglobulin (Ig) reduction, with no significant association between these Ig reductions and occurrence of infections or serious infections. The incidence of infections and serious infections did not increase with each additional year of UPLIZNA treatment.
Real-World Evidence Supports TAVNEOS Efficacy, Safety and Reduced Steroid Use
The AQUARIUS analyses (Abstracts #POS01356 and #POS08673), conducted at Massachusetts General Hospital and Northwestern University, evaluated the largest U.S. real-world cohort to date of patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) treated with TAVNEOS (n=159). The findings provide new insights into clinical outcomes in patients with ANCA-associated vasculitis and are consistent with the established clinical efficacy and safety profile of TAVNEOS in patients with severe active GPA or MPA.3,6
"Real-world experience with TAVNEOS across two large healthcare systems demonstrates that many patients can achieve meaningful disease control with reduced reliance on glucocorticoids when considering prior standard-of-care glucocorticoid regimens," said Naomi Patel, M.D., rheumatologist at Massachusetts General Hospital and study investigator. "Because prolonged steroid use carries significant risks for patients, these findings are encouraging and also suggest that shorter steroid tapers (e.g., < 2 months) may reduce overall glucocorticoid exposure without compromising effectiveness outcomes."
Key findings include:
Results highlighted variability in glucocorticoids (GCs) tapering strategies in real world practice and showed that many patients were able to taper to very low or no doses of GCs quickly.3 Observations underscored the complexity of managing ANCA-associated vasculitis and pointed to opportunities to further optimize treatment approaches to reduce steroid exposure while maintaining disease control.3,6 The safety profile observed in this real-world setting was consistent with the established safety profile in patients with severe active GPA or MPA.3,6 Among patients who experienced hepatic adverse events, all hepatic abnormalities were resolved. "People living with ANCA-associated vasculitis often have limited treatment options and may rely heavily on steroids for disease control," said Joyce Kullman, executive director, Vasculitis Foundation. "Given the challenges associated with long-term steroid use, these new data reinforce that TAVNEOS can help patients achieve disease control with reduced steroid use. For the vasculitis community, this may represent a step toward reducing treatment burden over time."
For more information on the full list of Amgen abstracts and presentation times, see below.
All Amgen-sponsored abstracts being presented at EULAR:
UPLIZNA® (inebilizumab)
Long-term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from Year 1 of the Open-Label Period of the Phase 3 MITIGATE Trial
Abstract #POS0440, Poster View 1 (Poster View Presentation), Wednesday, June 3 from 3:30–4:30 p.m. BST Immunogenicity and Impact of Anti-drug Antibodies on the Efficacy and Pharmacokinetics of Inebilizumab In MITIGATE, a Phase 3 Trial in IgG4-Related Disease
Abstract #POS0432, Poster View 1 (Poster View Presentation), Wednesday, June 3 from 3:30–4:30 p.m. BST Atypical IgG4-Related Disease: Re-Examining the Entry Criteria of the 2019 ACR/EULAR Classification Criteria
Abstract #POS0439, Poster View 1 (Poster View Presentation), Wednesday, June 3 from 3:30–4:30 p.m. BST Natural History of IgG4-RD: Patterns of Organ Involvement and Flare-associated Biomarker Changes in the MITIGATE Trial
Abstract #OP052, Basic and Clinical Abstract Sessions: Insights in Other Diseases (Oral Abstract Presentation), Wednesday, June 3 from 4:30–4:40 p.m. BST Serum IgG4 Elevation in IgG4-Related Disease: A Marker of Disease Phenotype and Organ Involvement
Abstract #OP056, Basic and Clinical Abstract Sessions: Insights in Other Diseases (Oral Abstract Presentation), Wednesday, June 3 from 5:10–5:20 p.m. BST Long-term Inebilizumab Treatment Results in Mild Immunoglobulin Reduction but No Increase in Infection Risk
Abstract #POS0089, Basic and Clinical Poster Tours: From Treatment to Outcome in Other Diseases (Poster Tour Presentation), Thursday, June 4 from 9:30–9:36 a.m. BST TAVNEOS (avacopan)
Reliability and Content Validity of a Definition of Severe Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Abstract #POS0627, Poster View I (Poster View Presentation), Wednesday, 3 June at 4:20 p.m. BST Clinical Outcomes by Glucocorticoid Duration in Individuals with Granulomatosis with Polyangiitis and Microscopic Polyangiitis Treated with Avacopan in a Real-World Setting in Two Large Healthcare Systems
Abstract #POS0867, Poster View IV (Poster View Presentation), Thursday, 4 June at 4:00 p.m. BST One Year Real-World Effectiveness and Safety with Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis in Two Large Healthcare Systems
Abstract #POS0135, Clinical Poster Tours: New frontiers in Small Vessel Vasculitis and Behcet's (Poster View Presentation), Thursday, 4 June from 1:36-1:42 p.m. BST KRYSTEXXA (pegloticase)
Association of Pegloticase-Induced Remission with Patient-Reported Quality of Life Outcomes in the MIRROR Randomized Controlled Trial
Abstract #POS0841, Poster View IV (Poster View Presentation), Wednesday, June 3 at 3:30 p.m. BST Reduction of Gout Flares with Pegloticase in Patients with or without Tophi at Baseline: A Post Hoc Analysis of the MIRROR Trial
Abstract #POS0421, Poster View I (Poster View Presentation), Thursday, June 4 at 4:00 p.m. BST Differences in Gout Management and Outcomes in Patients Referred From Primary Care to Rheumatology
Abstract #POS0843, Poster View IV (Poster View Presentation), Thursday, June 4 at 4:00 p.m. BST Baseline Predictors of Gout Remission During Intensive Urate-Lowering with Pegloticase: Post Hoc Analysis of the MIRROR Randomized Trial
Abstract #POS0169, Basic and Clinical Poster Tours: Advances in Gout and Crystal Disease (Poster Tour Presentation), Thursday, June 4 from 4:48–4:54 p.m. BST A Phase 4, Randomized, Double-blind Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous Pegloticase Administered Every 4 Weeks vs Every 2 Weeks with Weekly Methotrexate
Abstract #OP0294, Basic and Clinical Abstract Session: Beyond Hyperuricemia - New Insights into Gout Detection (Oral Abstract Presentation), Friday, June 5 from 9:05–9:15 a.m. BST OTEZLA (apremilast)
Efficacy of Apremilast in Early Oligoarticular Psoriatic Arthritis by Baseline Active Joint Count: A Post Hoc Analysis of the FOREMOST Study
Abstract #POS0490, Poster View I (Poster View Presentation), Wednesday, 3 June from 3:30-4:50 p.m. BST Partner-Led Abstracts
The Sjögren's Tool for Assessing Response (STAR) Demonstrates its Ability to Accurately Detect Treatment Efficacy in 15 Recent RCTs in Sjögren's Disease
Abstract #OP0125, Clinical Abstract Sessions: Positive Clinical Trials - A New Era in Sjögren's Disease (Oral Abstract Presentation), Wednesday, 3 June from 4:40-4:50 p.m. BST About UPLIZNA® (inebilizumab)
UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease process (autoantibody-producing CD19+ B cells, including plasmablasts and some plasma cells). The precise mechanism by which UPLIZNA exerts its therapeutic effects in IgG4-RD is unknown. After two initial infusions, patients need one dose of UPLIZNA every six months.7
About TAVNEOS® (avacopan)
TAVNEOS is an orally administered small molecule indicated as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis (GPA/MPA). It is a selective complement 5a receptor (C5aR) antagonist that targets inflammation by blocking the activity of C5a, a key driver of neutrophil activation. By inhibiting C5aR, TAVNEOS helps reduce inflammation while preserving other complement system functions. The precise mechanism by which TAVNEOS exerts its therapeutic effects in ANCA-associated vasculitis has not been fully established.8
UPLIZNA® (inebilizumab-cdon) U.S. INDICATIONS
UPLIZNA® (inebilizumab-cdon) is indicated in adult patients for the treatment of: anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD); Immunoglobulin G4-related disease (IgG4-RD); anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive (Ab+) generalized myasthenia gravis (gMG).
UPLIZNA U.S. IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
UPLIZNA® (inebilizumab-cdon) is contraindicated in patients with a history of a life-threatening infusion reaction to UPLIZNA, active hepatitis B infection, or active or untreated latent tuberculosis.
WARNINGS AND PRECAUTIONS
Infusion Reactions: Infusion reactions, including anaphylaxis, can occur. Symptoms can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or palpitations. Infusion reactions were observed in 9.3%, 7.4%, and 10.1% of patients treated with UPLIZNA during the randomized controlled periods (RCPs) of Study 1 in patients with NMOSD, Study 2 in patients with IgG4-RD, and Study 3 in patients with gMG, respectively. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions.
Administer pre-medication with a corticosteroid, an antihistamine, and an antipyretic. For life-threatening infusion reactions, immediately and permanently stop UPLIZNA and administer appropriate supportive treatment. For less severe infusion reactions, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment. Infections: Serious, including life-threatening or fatal, bacterial, fungal, and new or reactivated viral infections have been observed during and following completion of treatment with B-cell depleting therapies, including UPLIZNA. The most common infections reported by UPLIZNA-treated patients in the NMOSD randomized and open-label clinical trial periods for NMOSD were urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). In the IgG4-RD RCP, the most common infections reported by UPLIZNA-treated patients were urinary tract infection, influenza, and pneumonia. In the gMG RCP, the most common infections reported by UPLIZNA-treated patients were urinary tract infection and nasopharyngitis. Delay UPLIZNA administration in patients with an active infection until the infection is resolved.
Possible Increased Risk of Immunosuppressant Effects with Other Immunosuppressants: If combining UPLIZNA with another immunosuppressive therapy, consider the potential for increased immunosuppressive effects.Hepatitis B Virus (HBV) Reactivation: HBV reactivation has been observed with B-cell-depleting therapies, including UPLIZNA. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with B-cell depleting therapies. HBV reactivation was observed in a patient treated with UPLIZNA during the gMG clinical trial and in the postmarketing setting. Patients with active or chronic HBV infection were excluded from clinical trials. Perform HBV screening in all patients before initiation of treatment. Do not administer to patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for HBsAg and positive for HBcAb, or who are carriers of HBV (i.e., HBsAg+), consult liver disease experts before starting and during treatment.Progressive Multifocal Leukoencephalopathy (PML): Although no confirmed cases of PML were identified in UPLIZNA clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. In UPLIZNA clinical trials one subject died following the development of new brain lesions for which a definitive diagnosis could not be established, though the differential diagnosis included an atypical NMOSD relapse, PML, or acute disseminated encephalomyelitis. At the first sign or symptom suggestive of PML, withhold UPLIZNA and perform an appropriate diagnostic evaluation. MRI findings may be apparent before clinical signs or symptoms. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.Tuberculosis
Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating UPLIZNA. Consider anti-tuberculosis therapy prior to initiation of UPLIZNA in patients with a history of latent active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating anti-tuberculosis therapy is appropriate before starting treatment.Vaccinations
Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of UPLIZNA. The safety of immunization with live or live-attenuated vaccines following UPLIZNA therapy has not been studied, and vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion.
Vaccination of Infants Born to Mothers Treated with UPLIZNA During Pregnancy
In infants of mothers exposed to UPLIZNA during pregnancy, do not administer live or live-attenuated vaccines before confirming recovery of B-cell counts in the infant. Depletion of B cells in these exposed infants may increase the risks from live or live-attenuated vaccines. Non-live vaccines, as indicated, may be administered prior to recovery from B-cell and immunoglobulin level depletion, but consultation with a qualified specialist should be considered to assess whether a protective immune response was mounted.
Reductions in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA treatment. Monitor the levels of quantitative serum immunoglobulins during treatment with UPLIZNA, especially in patients with opportunistic or recurrent infections, and until B-cell repletion after discontinuation of therapy. Consider discontinuing UPLIZNA therapy if a patient with low immunoglobulin G or M develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.
Fetal Risk: Based on animal data, UPLIZNA can cause fetal harm due to B-cell lymphopenia and reduce antibody response in offspring exposed to UPLIZNA even after B-cell repletion. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other B-cell-depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception while receiving UPLIZNA and for at least 6 months after the last dose. ADVERSE REACTIONS
The most common adverse reactions (at least 10% of patients treated with UPLIZNA and greater than placebo): urinary tract infection and arthralgia in NMOSD; urinary tract infection and lymphopenia in IgG4-RD; headache and infusion-related reactions in gMG. Please see UPLIZNA® full Prescribing Information
TAVNEOS (avacopan) U.S. INDICATION
TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.
TAVNEOS U.S. IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Serious hypersensitivity to avacopan or to any of the excipients.
WARNINGS AND PRECAUTIONS
Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events. In the postmarketing setting, vanishing bile duct syndrome (VBDS) as a consequence of liver injury, including cases with a fatal outcome, has been reported. These events occurred predominantly in Japan in patients aged 65 years and older, but VBDS may affect patients of any age or ethnicity who are receiving TAVNEOS. Obtain liver test panel before initiating TAVNEOS, every 4 weeks after start of therapy for 6 months and as clinically indicated thereafter. For patients of Japanese descent, consider more frequent laboratory testing: every 2 weeks after the start of therapy for the first 3 months, followed by laboratory testing every 4 weeks for the next 3 months of treatment, and as clinically indicated thereafter. If a patient receiving treatment with TAVNEOS presents with an elevation in alanine aminotransferase [ALT] or aspartate aminotransferase [AST] to >3 times the upper limit of normal, evaluate promptly and consider pausing treatment as clinically indicated. If AST or ALT is > 5 times the upper limit of normal (ULN), or ALT or AST > 3 times the ULN with total bilirubin > 2 times the ULN, or alkaline phosphatase ≥ 2 times the ULN, or if the patient has clinical symptoms such as jaundice or pruritus, discontinue TAVNEOS until TAVNEOS-induced liver injury is ruled out. Immediately and permanently discontinue TAVNEOS if VBDS is suspected. TAVNEOS is not recommended for patients with active, untreated, and/or uncontrolled chronic liver disease (e.g., chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis) and cirrhosis. Consider the risks and benefits before administering this drug to a patient with liver disease. Serious Hypersensitivity Reactions: Cases of angioedema occurred in a clinical trial, including 1 serious event requiring hospitalization. Discontinue immediately if angioedema occurs and manage accordingly. TAVNEOS must not be readministered unless another cause has been established. Hepatitis B Virus (HBV) Reactivation: Hepatitis B reactivation, including life-threatening hepatitis B, was observed in the clinical program. Screen patients for HBV. For patients with evidence of prior infection, consult with physicians with expertise in HBV and monitor during TAVNEOS therapy and for 6 months following. If patients develop HBV reactivation, immediately discontinue TAVNEOS and concomitant therapies associated with HBV reactivation, and consult with experts before resuming. Serious Infections: Serious infections, including fatal infections, have been reported in patients receiving TAVNEOS. The most common serious infections reported in the TAVNEOS group were pneumonia and urinary tract infections. Avoid use of TAVNEOS in patients with active, serious infection, including localized infections. Consider the risks and benefits before initiating TAVNEOS in patients with chronic infection, at increased risk of infection, or who have been to places where certain infections are common. ADVERSE REACTIONS
The most common adverse reactions (≥5% of patients and higher in the TAVNEOS group vs. prednisone group) were nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia. DRUG INTERACTIONS
Avoid co-administration of TAVNEOS with strong and moderate CYP3A4 enzyme inducers. Reduce TAVNEOS dose when co-administered with strong CYP3A4 enzyme inhibitors to 30 mg once daily. Consider dose reduction of CYP3A4 substrates when co-administering TAVNEOS. Co‑administration of avacopan and 40 mg simvastatin increases the systemic exposure of simvastatin. While taking TAVNEOS, limit simvastatin dosage to 10 mg daily (or 20 mg daily for patients who have previously tolerated simvastatin 80 mg daily for at least one year without evidence of muscle toxicity). Consult the concomitant CYP3A4 substrate product information when considering administration of such products together with TAVNEOS. TAVNEOS is available as a 10 mg capsule.
Please see Full Prescribing Information and Medication Guide for TAVNEOS.
To report a suspected adverse event, call 1-833-828-6367. You may report to the FDA directly by visiting www.fda.gov/medwatch or calling 1-800-332-1088.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.
More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.
Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average® and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.
Stone J, et al. Oral Presentation at European Alliance of Associations for Rheumatology (EULAR) 2026 Congress. June 3-6, 2026: Abstract #OP052. Stone J, et al. Poster Presentation at European Alliance of Associations for Rheumatology (EULAR) 2026 Congress. June 3-6, 2026: Abstract #POS0440. Patel, N, et al. Poster Presentation at European Alliance of Associations for Rheumatology (EULAR) 2026 Congress. June 3-6, 2026: Abstract #POS0867. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-551. Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702-714. Patel, N, et al. Poster Presentation at European Alliance of Associations for Rheumatology (EULAR) 2026 Congress. June 3-6, 2026: Abstract #POS0135. UPLIZNA (inebilizumab) Summary of Product Characteristics (SmPC). Available at Uplizna, INN-inebilizumab. Last accessed May 2026. TAVNEOS (avacopan) Summary of Product Characteristics (SmPC). Available at Tavneos, INN-avacopan. Last accessed May 2026. KRYSTEXXA (pegloticase) Summary of Product Characteristics (SmPC). Available at Krystexxa, INN-pegloticase. Last accessed May 2026. SOURCE Amgen
June 03, 2026 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET.
The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa [email protected]
, /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab's potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.
If you currently own RARE and purchased prior to August 03, 2023 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) EVP Lee Scott Golden sold 829 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $67.99, for a total value of $56,363.71. Following the completion of the sale, the executive vice president directly owned 79,115 shares in the company, valued at $5,379,028.85. This represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Lee Scott Golden also recently made the following trade(s):
On Thursday, March 5th, Lee Scott Golden sold 10,000 shares of PTC Therapeutics stock. The stock was sold at an average price of $63.38, for a total value of $633,800.00. On Wednesday, February 18th, Lee Scott Golden sold 2,484 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.36, for a total value of $172,290.24. On Thursday, January 8th, Lee Scott Golden sold 866 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.45, for a total value of $66,205.70. On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total value of $49,742.16. On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $103,113.00. PTC Therapeutics Stock Up 1.7% NASDAQ:PTCT opened at $68.90 on Tuesday. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50. The company has a market capitalization of $5.70 billion, a P/E ratio of 8.90 and a beta of 0.55. The stock’s fifty day moving average is $68.91 and its two-hundred day moving average is $71.17.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The firm had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. During the same period in the previous year, the company posted ($0.85) EPS. PTC Therapeutics’s revenue was down 22.7% on a year-over-year basis. Sell-side analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.
Analysts Set New Price Targets PTCT has been the subject of several analyst reports. Wall Street Zen cut PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. TD Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Bank of America decreased their target price on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Wells Fargo & Company decreased their target price on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a research report on Friday, February 20th. Finally, Jefferies Financial Group cut PTC Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $91.00 to $76.00 in a research report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, PTC Therapeutics has an average rating of “Moderate Buy” and an average target price of $82.71.
Check Out Our Latest Analysis on PTCT
Hedge Funds Weigh In On PTC Therapeutics A number of large investors have recently modified their holdings of PTCT. Jefferies Financial Group Inc. purchased a new stake in PTC Therapeutics during the third quarter worth $97,252,000. Janus Henderson Group PLC increased its position in shares of PTC Therapeutics by 28.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock valued at $368,587,000 after buying an additional 1,077,776 shares in the last quarter. State Street Corp raised its stake in shares of PTC Therapeutics by 34.2% during the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock worth $319,497,000 after buying an additional 1,071,343 shares during the last quarter. Toronto Dominion Bank raised its stake in shares of PTC Therapeutics by 27.5% during the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after buying an additional 891,690 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in PTC Therapeutics by 4,013.1% in the 4th quarter. BNP Paribas Financial Markets now owns 828,662 shares of the biopharmaceutical company’s stock valued at $62,945,000 after acquiring an additional 808,515 shares during the last quarter.
PTC Therapeutics Company Profile (Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Read More Five stocks we like better than PTC Therapeutics
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINESound Group (NASDAQ:SOGP) Director Ming Zhang Sells 1,001 Shares of Stock
NEXT HEADLINE »Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Richard Malamut Sells 590 Shares of Stock
Burney Co. bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,569 shares of the biopharmaceutical company’s stock, valued at approximately $2,018,000.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Smartleaf Asset Management LLC boosted its stake in shares of PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. boosted its stake in shares of PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares during the period. IFP Advisors Inc boosted its stake in shares of PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 310 shares during the period. Arizona State Retirement System boosted its stake in shares of PTC Therapeutics by 2.0% in the third quarter. Arizona State Retirement System now owns 21,101 shares of the biopharmaceutical company’s stock valued at $1,295,000 after purchasing an additional 406 shares during the period. Finally, Mariner LLC boosted its stake in shares of PTC Therapeutics by 5.1% in the third quarter. Mariner LLC now owns 8,745 shares of the biopharmaceutical company’s stock valued at $537,000 after purchasing an additional 426 shares during the period.
Analyst Ratings Changes Several brokerages have recently weighed in on PTCT. Cantor Fitzgerald restated an “overweight” rating on shares of PTC Therapeutics in a research note on Friday, February 20th. Weiss Ratings restated a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Truist Financial upgraded shares of PTC Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Morgan Stanley upped their target price on shares of PTC Therapeutics from $90.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, February 23rd. Finally, Jefferies Financial Group cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $91.00 to $76.00 in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $84.40.
Read Our Latest Stock Report on PTC Therapeutics
Insider Transactions at PTC Therapeutics In other PTC Therapeutics news, Director Stephanie Okey sold 15,167 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $70.00, for a total transaction of $1,061,690.00. Following the sale, the director directly owned 8,000 shares of the company’s stock, valued at approximately $560,000. This represents a 65.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Neil Gregory Almstead sold 52,003 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $69.04, for a total transaction of $3,590,287.12. Following the sale, the insider directly owned 60,137 shares in the company, valued at $4,151,858.48. This trade represents a 46.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 123,642 shares of company stock valued at $8,432,528 over the last ninety days. 5.50% of the stock is currently owned by corporate insiders.
PTC Therapeutics Price Performance PTCT opened at $70.42 on Tuesday. The stock has a market capitalization of $5.83 billion, a PE ratio of 9.10 and a beta of 0.55. The firm’s fifty day moving average price is $68.37 and its 200 day moving average price is $71.54. PTC Therapeutics, Inc. has a 12-month low of $35.95 and a 12-month high of $87.50.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The company had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. The company’s revenue was down 22.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.85) earnings per share. On average, equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.
PTC Therapeutics Profile (Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Further Reading Five stocks we like better than PTC Therapeutics
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEVallourec (EPA:VK) Shares Cross Above 200 Day Moving Average – What’s Next?
NEXT HEADLINE »Choreo LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX
, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation.
The inducement grant was approved by PTC's Compensation Committee on April 13, 2026, and is being made as an inducement material to the employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of $70.42 per share, the closing price of PTC's common stock on April 13, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the employee's new hire date until fully vested, subject to the employee's continued service with the company through the vesting dates.
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.
For more information, please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]
, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, May 7, 2026, at 4:30 p.m. ET.
To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.
For more information, please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]
